TransCode Therapeutics Analyst Ratings
BenzingaApr 16 10:49 ET
Analysts Offer Insights on Healthcare Companies: Syros Pharmaceuticals (SYRS), Alpine Immune Sciences (ALPN) and TransCode Therapeutics (RNAZ)
TipRanksNov 15, 2023 06:21 ET
HC Wainwright & Co. Reiterates Buy on TransCode Therapeutics, Maintains $3 Price Target
BenzingaOct 24, 2023 12:03 ET
TransCode Therapeutics Analyst Ratings
BenzingaOct 24, 2023 12:00 ET
Promising Preliminary Clinical and Preclinical Results Bolster Buy Rating for TransCode Therapeutics: An Analysis by Emily Bodnar
TipRanksOct 24, 2023 11:56 ET
TransCode Therapeutics Analyst Ratings
BenzingaAug 15, 2023 06:39 ET
H.C. Wainwright Initiates a Buy Rating on TransCode Therapeutics (RNAZ)
TipRanksAug 15, 2023 06:15 ET
Analysts Offer Insights on Healthcare Companies: TransCode Therapeutics (RNAZ), Tarsus Pharmaceuticals (TARS) and Roivant Sciences (ROIV)
TipRanksJun 29, 2023 06:20 ET
TransCode Therapeutics (RNAZ) Gets a Buy From H.C. Wainwright
TipRanksDec 29, 2022 11:10 ET
H.C. Wainwright Sticks to Its Buy Rating for TransCode Therapeutics (RNAZ)
TipRanksDec 1, 2022 09:45 ET
HC Wainwright Adjusts Price Target on TransCode Therapeutics to $6 From $10, Maintains Buy Rating
MT NewswiresNov 15, 2022 10:48 ET
TransCode Therapeutics Analyst Ratings
Benzinga Analyst RatingsNov 15, 2022 06:35 ET
H.C. Wainwright Remains a Buy on TransCode Therapeutics (RNAZ)
TipRanksAug 16, 2022 06:20 ET
HC Wainwright Starts TransCode Therapeutics at Buy With $10 Price Target
MT NewswiresJun 7, 2022 06:56 ET
Transcode Therapeutics Price Target Announced at $10.00/Share by HC Wainwright & Co.
Dow JonesJun 7, 2022 06:32 ET
Transcode Therapeutics Initiated at Buy by HC Wainwright & Co.
Dow JonesJun 7, 2022 06:32 ET
TransCode Therapeutics analyst ratings
Benzinga Analyst RatingsJun 7, 2022 06:24 ET
HC Wainwright & Co. Initiates Coverage On TransCode Therapeutics with Buy Rating, Announces Price Target of $10
Benzinga Real-time NewsJun 7, 2022 06:24 ET
No Data
No Data